Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Evotec SE ADR

Healthcare US EVO

2.58USD
-0.03(1.15%)

Last update at 2026-06-18T20:00:00Z

Day Range

2.562.62
LowHigh

52 Week Range

2.314.80
LowHigh

Fundamentals

  • Previous Close 2.61
  • Market Cap1156.15M
  • Volume38552
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA19.17M
  • Revenue TTM788.37M
  • Revenue Per Share TTM2.22
  • Gross Profit TTM 114.22M
  • Diluted EPS TTM-0.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -123.31319M -193.97700M -103.84100M -153.95700M 236.98M
Minority interest - - - 0.00000M 0.00000M
Net income -99.43146M -196.07800M -83.91300M -175.65500M 215.51M
Selling general administrative 175.97M 170.72M 152.74M 142.70M 96.02M
Selling and marketing expenses - 17.48M 16.87M 13.49M 9.42M
Gross profit 62.66M 114.88M 175.05M 174.06M 151.54M
Reconciled depreciation 99.48M 101.62M 92.98M 81.66M 70.40M
Ebit -135.31216M -182.27800M -7.33089M 12.49M 27.32M
Ebitda -39.76221M -80.66000M -7.16300M 94.15M 94.93M
Depreciation and amortization 95.55M 101.62M 0.17M 81.66M 67.61M
Non operating income net other - - - - -
Operating income -135.31216M -142.52200M -107.08800M 12.49M 27.32M
Other operating expenses 892.57M 939.49M 888.51M 730.60M 576.36M
Interest expense 13.87M 11.70M 11.74M 13.15M 9.25M
Tax provision 16.75M 2.10M 3.32M 21.70M 21.47M
Interest income 4.42M 2.44M 9.26M 8.34M 2.27M
Net interest income -10.01800M -9.26400M -2.47600M -4.81400M -6.98200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -23.88172M 2.10M -40.68000M 21.70M 21.47M
Total revenue 757.26M 796.97M 781.43M 751.45M 618.03M
Total operating expenses 197.97M 257.40M 282.14M 153.22M 109.86M
Cost of revenue 694.60M 682.09M 606.38M 577.38M 466.49M
Total other income expense net 12.00M -51.45500M 3.25M -166.45200M 209.66M
Discontinued operations - - - - -
Net income from continuing ops -103.51700M -196.07900M -83.91300M -175.65500M 215.51M
Net income applicable to common shares - - - - 215.51M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1778.00M 1912.50M 2299.05M 2257.25M 2235.16M
Intangible assets 31.56M 26.44M 15.45M 23.82M 30.85M
Earning assets - - - - -
Other current assets 43.71M 35.66M 64.11M 40.18M 20.68M
Total liab 964.64M 959.98M 1179.14M 1070.06M 857.48M
Total stockholder equity 813.36M 952.52M 1119.91M 1187.18M 1377.68M
Deferred long term liab - - - - -
Other current liab 91.52M 84.21M 73.31M 87.38M 74.53M
Common stock 177.70M 177.55M 177.19M 176.95M 176.61M
Capital stock 177.78M 177.55M 177.19M 176.95M 176.61M
Retained earnings -775.55678M -672.37000M -476.28900M -392.37700M -216.42100M
Other liab - - - - 70.65M
Good will 272.25M 282.85M 275.63M 274.82M 257.57M
Other assets - - 0.00000M - 79.34M
Cash 418.34M 306.39M 510.91M 415.15M 699.33M
Cash and equivalents - - - - -
Total current liabilities 367.92M 344.58M 464.57M 337.71M 324.52M
Current deferred revenue 108.02M 109.81M 107.86M 136.67M 126.78M
Net debt 29.16M 137.15M 115.29M 91.52M -186.40900M
Short term debt 103.64M 50.80M 149.09M 16.38M 50.61M
Short long term debt 104.72M 50.80M - 1.56M 36.14M
Short long term debt total 447.50M 443.54M 626.20M 506.67M 512.92M
Other stockholder equity 1456.30M 1454.69M 1449.65M 1440.01M 1430.14M
Property plant equipment - - - - 484.60M
Total current assets 762.62M 681.96M 903.16M 1073.67M 1100.94M
Long term investments 52.63M 42.15M 142.09M 150.33M 287.01M
Net tangible assets - - - - 1089.27M
Short term investments 57.85M 90.41M 93.20M 314.83M 159.17M
Net receivables 213.42M 218.38M 204.06M 256.74M 176.75M
Long term debt 344.01M 392.74M - 328.30M 326.34M
Inventory 29.30M 31.12M 30.89M 29.82M 25.79M
Accounts payable 64.74M 85.79M 134.32M 97.28M 72.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -45.08680M -7.34700M -30.64300M -37.40200M -12.63800M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 36.84M 37.82M 95.23M 74.08M 56.84M
Deferred long term asset charges - - - - -
Non current assets total 1015.38M 1230.54M 1395.89M 1183.58M 1134.22M
Capital lease obligations 22.18M - - 176.82M 150.44M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 31.97M -71.18700M -13.29100M -415.82300M -117.12600M
Change to liabilities - - - 0.00000M 94.42M
Total cashflows from investing activities 159.86M -71.18700M - - -243.85500M
Net borrowings -29.41800M -152.07300M - - -5.89200M
Total cash from financing activities -30.93395M -161.42100M 84.82M -52.41400M 398.43M
Change to operating activities - - - - -55.87000M
Net income -99.43146M -196.07800M -83.91300M -175.65500M 215.51M
Change in cash 148.32M -204.52200M 95.75M -284.17100M 276.75M
Begin period cash flow 270.02M 510.91M 415.15M 699.33M 422.58M
End period cash flow 418.34M 306.39M 510.91M 415.15M 699.33M
Total cash from operating activities -9.06455M 18.22M 33.95M 203.11M 122.24M
Issuance of capital stock - 0.00000M 0.22M 0.35M 403.13M
Depreciation 95.55M 101.62M 99.92M 81.66M 67.61M
Other cashflows from investing activities - -2.78200M - - -
Dividends paid 0.00000M 0.00000M 0.00000M - -
Change to inventory -9.18461M -2.68700M - -4.41000M -11.65300M
Change to account receivables -27.59514M -40.74200M - -38.42900M -48.03200M
Sale purchase of stock -1.54800M 0.00000M - - -
Other cashflows from financing activities -22.70603M -9.34800M -12.63400M 0.34M 31.99M
Change to netincome - - - - -158.60000M
Capital expenditures 69.68M 132.24M 216.00M 181.35M 118.94M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -58.40423M -68.20700M -9.94400M 119.26M -2.28100M
Stock based compensation 3.78M 5.04M 9.63M 9.92M 7.80M
Other non cash items 39.11M 173.75M 232.33M 160.20M -171.47100M
Free cash flow -78.74351M -114.01700M -182.04700M 21.75M 3.29M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EVO
Evotec SE ADR		 -0.03 1.15% 2.58 - 53.48 1.47 1.17 1.21 35.02
ZTS
Zoetis Inc		 1.45 1.88% 78.71 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 - -% 30.75 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.33 0.76% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE ADR

Essener Bogen 7, Hamburg, Germany, 22419

Key Executives

Name Title Year Born
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D. Chairman of Management Board & CEO 1968
Mr. Enno Spillner CFO & Member of Management Board 1970
Dr. Cord Dohrmann Ph.D. Chief Scientific Officer & Member of Management Board 1964
Dr. Craig Johnstone COO & Member of Management Board 1970
Dr. Matthias Evers Chief Bus. Officer & Member of Management Board 1973
Ms. Anja Bosler Principal Accounting Officer and Sr. VP of Group Accounting NA
Mr. Volker Braun Sr. VP and Global Head of Investor Relations & ESG NA
Dr. Christian Dargel EVP Global Head of Legal & Compliance NA
Gabriele Hansen Sr. VP & Head of Global Corp. Communications & Marketing NA
Ms. Monika Conradt Global Head of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions